UPDATE: The 2024 KDIGO CKD Evaluation and Management Guidelines are here
In the complicated and ever-changing world of healthcare, having a set of clear evidence-based recommendations for screening, diagnosis and management can improve quality of care. Enter, the latest iteration of the KDIGO (Kidney Disease: Improving Global Outcomes) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, which was recently published in a supplement to Kidney International. Intended for all healthcare professionals involved in the assessment and management of people living with chronic kidney disease (CKD), this key resource provides clinicians with practical and actionable recommendations regarding the following:
- Classification of CKD
- Evaluation of CKD
- CKD risk assessment
- Management of the complications of CKD
- Medication management
- Delivering patient-centred care across various settings throughout the patient journey.
Considering the recent advances in the field, this iteration has specifically updated the guidance regarding measurements of eGFR and albuminuria, and the use of risk prediction equations. The guidelines also suggest how to individualise treatments for kidney and cardiovascular risk reduction, such as for those at the extremes of age.
During their appraisal of the latest evidence, the authors of the guideline identified key research priorities. Addressing these unanswered questions will further our understanding of CKD and provide us with the opportunity to address unmet needs identified in the current guidelines.
Don’t have time to read the full guideline? Don’t worry, KDIGO has kindly prepared highlights relevant to you. Access the highlight presentations, executive summary and full guidance here.
